Mikael Engblom - Cellink AB Interim Officer
| CLLKF Stock | USD 3.65 0.33 8.29% |
Insider
Mikael Engblom is Interim Officer of Cellink AB
| Age | 46 |
| Phone | 46 7 08 30 08 90 |
| Web | https://www.bico.com |
Cellink AB Management Efficiency
The company has return on total asset (ROA) of (0.025) % which means that it has lost $0.025 on every $100 spent on assets. This is way below average. Cellink AB's management efficiency ratios could be used to measure how well Cellink AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Joel Bradus | Nexalin Technology | N/A | |
| Chad Clouse | Aurora Spine | N/A | |
| Jason Cook | Bluejay Diagnostics | 43 | |
| Mark Feinberg | Bluejay Diagnostics | N/A | |
| Leigh Salvo | IRIDEX | N/A | |
| Richard Areglado | Brainsway | 60 | |
| Avner Hagai | Brainsway | 69 | |
| John Esq | Ainos Inc | 57 | |
| Yiftach Roth | Brainsway | 54 | |
| Mark MD | Bluejay Diagnostics | N/A | |
| Fuad Ahmad | IRIDEX | 55 | |
| Kevin Vance | Bluejay Diagnostics | 67 | |
| HuiLan Wu | Ainos Inc | 63 | |
| Pr Zangen | Brainsway | 55 | |
| Moria Ankri | Brainsway | 40 | |
| Brad Nagel | Electromed | N/A | |
| David MD | Nexalin Technology | 64 | |
| David Meyer | Aurora Spine | N/A | |
| Laszlo Garamszegi | Aurora Spine | 52 | |
| Trent Northcutt | Aurora Spine | 56 | |
| Christopher Jako | Brainsway | 55 | |
Management Performance
| Return On Equity | 0.0068 | |||
| Return On Asset | -0.025 |
Cellink AB Leadership Team
Elected by the shareholders, the Cellink AB's board of directors comprises two types of representatives: Cellink AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellink. The board's role is to monitor Cellink AB's management team and ensure that shareholders' interests are well served. Cellink AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellink AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erik Gatenholm, CEO, CoFounder | ||
| Lotta Bus, Gen SVP | ||
| Karin Danielsson, Global Director | ||
| Asa Hillsten, VP Relations | ||
| Itedale Redwan, Chief Bioprinting | ||
| Erica Bell, VP Officer | ||
| Niclas Emanuelsson, Head Operations | ||
| Mikael Engblom, Interim Officer | ||
| Artur Aira, Sr Bioprinting | ||
| Jason Clifton, Head Operations | ||
| Hector Martinez, CoFounder VP |
Cellink Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Cellink AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0068 | |||
| Return On Asset | -0.025 | |||
| Profit Margin | 0.02 % | |||
| Current Valuation | 973.88 M | |||
| Shares Outstanding | 69.07 M | |||
| Shares Owned By Insiders | 38.50 % | |||
| Shares Owned By Institutions | 26.80 % | |||
| Price To Book | 1.23 X | |||
| Price To Sales | 4.61 X | |||
| Revenue | 1.26 B |
Currently Active Assets on Macroaxis
Other Information on Investing in Cellink Pink Sheet
Cellink AB financial ratios help investors to determine whether Cellink Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cellink with respect to the benefits of owning Cellink AB security.